Animal Vaccines Market (2026 - 2033) Size, Share & Trends Analysis Report By Product (Subunit, Inactivated), By Animal (Livestock, Companion), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts

Animal Vaccines Market Summary

The global animal vaccines market size was estimated at USD 14.8 billion in 2025 and is projected to reach USD 32.4 billion by 2033, growing at a CAGR of 10.5% from 2026 to 2033. Some of the factors driving market growth are increasing cattle disease outbreaks, rising advancements in innovative therapies, and growing emphasis on the One Health approach & zoonotic disease prevention.

The increasing frequency and severity of livestock disease outbreaks are significantly driving demand for animal vaccines globally. Some of the diseases, such as foot-and-mouth disease (FMD), avian influenza, African swine fever, and lumpy skin disease, have led to substantial economic losses and disruptions in food supply chains. According to a report, African Swine Fever caused over USD112.5 billion in losses during 2019, while Foot-and-Mouth Disease results in annual losses of USD21 billion, highlighting the significant economic burden of livestock diseases globally. In addition, governments and international organizations are implementing large-scale immunization programs to control outbreaks and prevent cross-border disease transmission. In addition, rising global trade of livestock products has increased the need for stringent biosecurity and vaccination protocols. This trend is particularly prominent in developing economies, where livestock farming is a critical source of livelihood.

In addition, the emergence of mRNA and next-generation vaccine technologies is transforming the market by enabling faster, more efficient, and targeted vaccine development. These mRNA-based platforms allow rapid design and scalability, making them highly effective in responding to emerging and mutating pathogens, unlike traditional vaccines. For instance, in July 2025, an mRNA FMD vaccine was developed with Friedrich-Loeffler-Institut that demonstrated full protection in cattle and reduced virus transmission, highlighting its effectiveness and advantages over traditional vaccine production methods. These advanced vaccines offer improved safety profiles and enhanced immune responses across companion and livestock animals. In addition, biopharmaceutical companies are investing in RNA-based, recombinant, and vector-based vaccines in large numbers to address complex and previously unmet veterinary needs. Furthermore, the integration of advanced manufacturing technologies supports large-scale production and commercialization.

Furthermore, growing emphasis on the One Health approach, which integrates human, animal, and environmental health, is a key market driver. Many of the emerging infectious diseases are zoonotic in nature, and preventing disease transmission from animals to humans has become a global priority. According to the CDC report of April 2025, scientists estimated more than 60% of known human infectious diseases originate from animals, whereas about 75% of emerging infections are zoonotic, highlighting the critical role of animal health management and vaccination. Thus, vaccination of animals plays a crucial role in reducing the risk of zoonotic outbreaks, safeguarding public health, and minimizing economic losses. In addition, governments, health organizations, and veterinary stakeholders are collaborating in large numbers to implement comprehensive immunization strategies and surveillance systems. For instance, in August 2025, the Pirbright Institute and CPI partnered to advance RNA livestock vaccines, accelerating innovation, scalable production, and rapid disease response capabilities. As awareness and regulatory support increase, the focus on preventive animal healthcare is strengthening, thereby driving sustained demand for vaccines.

Pricing Analysis by AWA, Vaccines, (USD)

Market Concentration & Characteristics

The market is characterized as moderately concentrated, dominated by key players such as Zoetis, Merck Animal Health, Boehringer Ingelheim, and Elanco Animal Health. These companies leverage strong R&D, global distribution, and strategic collaborations, while regional players intensify competition through cost-effective and specialized vaccine offerings.

The market demonstrates a high degree of innovation. Innovations in animal vaccines have become increasingly significant in veterinary medicine, driven by advances in biotechnology, changing disease landscapes, and growing awareness of animal welfare. Key trends and innovations include recombinant DNA vaccines, which use genetic engineering to produce antigens that stimulate the immune response. They are safer than traditional vaccines because they don't require live pathogens. Recombinant vaccines are effective for diseases like rabies, feline leukemia, and foot-and-mouth disease.

There exists a moderate to high level of mergers and acquisitions activity, indicative of ongoing consolidation, strategic acquisitions, and partnerships among industry players. For instance, in January 2025, Ceva Sante Animale acquired Scout Bio to expand into veterinary biologics and gene therapies.

The market experiences a high impact of regulations. Vaccines must undergo a rigorous approval process before they are marketed. This involves laboratory research, clinical trials, and reviews of safety, efficacy, and quality. In the U.S., the Center for Veterinary Biologics (CVB), under the U.S. Department of Agriculture (USDA), regulates veterinary vaccines. Moreover, manufacturers must adhere to Good Manufacturing Practices (GMP) to ensure the quality and consistency of vaccines. GMP compliance is regularly monitored through inspections.

Initiatives by major competitors in the market cause moderate regional growth operations. For instance, in February 2026, during BioAsia 2026, multiple projects, including a BSL-3 animal vaccine facility and AI-driven innovation hubs, were announced in India, strengthening regional manufacturing and research capabilities of animal vaccines.

Product Insights

The attenuated live vaccines segment dominated the market with the largest revenue share of 34.6% in 2025. The most traditional immunization technique in the veterinary industry is live attenuation. The major advantages of these vaccines are that they are cheap and offer better immune responses. Moreover, doses are required less frequently and provide long-lasting immunity. Such vaccines are, therefore, useful for a large number of animals, as small dosages will ensure protection against diseases. In addition, novel vaccine development is also driving market growth. For instance, in October 2025, HIPRA launched EVANOVO, Europe’s first live attenuated in-ovo coccidiosis vaccine for poultry, offering early, uniform protection and optimizing hatchery vaccination processes alongside other vaccines. Due to these advantages, the demand for these vaccines is expected to grow over the coming years.

The DNA & RNA vaccines segment is the fastest growing in the market over the forecast period, driven by rapid technological advancements, enabling faster, scalable, and targeted vaccine development. These platforms support effective control of emerging livestock and zoonotic diseases while enhancing immune responses. In addition, research in RNA and DNA vaccines is advancing market growth. For instance, in April 2026, Iowa State University developed AI-powered livestock vaccines predicting viral mutations, enabling multi-epitope designs to combat rapidly evolving diseases like PRRS and infectious bronchitis in animals. Such innovations play a critical role in driving market growth. Moreover, mRNA vaccines help reduce antibiotic overuse by offering precise preventive solutions, supporting efforts against antimicrobial resistance. Their role in strengthening animal immunity against zoonotic infections aligns with the One Health approach, further accelerating adoption and innovation across veterinary healthcare systems.

Animal Insights

Livestock dominated the market with the highest revenue share in 2025. This can be attributed to factors such as the rising livestock population, supportive government initiatives, and the outbreak of diseases among cattle and sheep. The livestock population has increased, with significant growth in cattle, sheep, pigs, and poultry being raised for meat production. For instance, as of October 2024, the Department of Animal Husbandry and Dairying, India’s total livestock population has reached 536.76 million, reflecting a 4.8% increase compared to the 2012 Livestock Census, indicating steady growth in the animal husbandry sector. To preserve health and productivity, this sizable animal herd requires extensive vaccinations, driving the demand for animal vaccines.

Companion is the fastest-growing segment during the forecast period. House pets and ferrets carry canine distemper virus and require strict preventive vaccination, as no post-infection treatment is available. The Morbillivirus affects dogs, foxes, raccoons, and wolves to cause distemper and is transmitted through the air and other modes of contact between infected and healthy animals. Immunization of dogs is essential as canine distemper destroys the respiratory, urogenital, and gastrointestinal tract. Dogs suffering from gastrointestinal tract bacterial infections and newborn pups are more susceptible to this disease. Several canine distemper vaccines are available, including Megavac 6 and 7, DHPPi/L Vaccine, DHP, and Vanguard.

Route Of Administration

The injectable segment held the largest share in 2025. The segment’s growth is influenced by its high efficacy, rapid immune response, and precise dosage delivery across livestock and companion animals. Injectable vaccines are widely preferred for mass vaccination programs due to their proven reliability in controlling infectious diseases such as foot-and-mouth disease and rabies. In addition, increasing disease outbreaks, government-led immunization initiatives, and growing awareness of preventive healthcare further boost demand. Furthermore, advancements in formulation technologies and combination vaccines enhance convenience, supporting the continued growth of the injectable segment.

The oral segment is the fastest-growing over the forecast period, driven by its ease of administration, reduced stress on animals, and suitability for mass immunization, particularly in poultry, swine, and wildlife. Oral delivery eliminates the need for skilled labor and minimizes handling risks, making it cost-effective for large-scale operations. In addition, growing demand for efficient vaccination in remote and farm settings supports adoption.

Distribution Channel Insights

The veterinary supply distributors segment dominated the market in 2025, driven by expanding livestock and companion animal populations, increasing vaccination programs, and rising demand for efficient cold chain logistics. Distributors play a critical role in ensuring the timely availability and last-mile delivery of vaccines to farms, clinics, and rural areas. In addition, growing awareness of preventive animal healthcare and government-supported immunization campaigns is strengthening distribution networks. In addition, digital supply chain integration and partnerships with manufacturers further enhance accessibility, supporting consistent market growth.

The e-commerce segment is the fastest-growing in the market, attributed to increasing digital adoption among veterinarians and farmers, enabling convenient procurement of vaccines and related products. Online platforms improve accessibility, especially in remote areas, while offering price transparency and a wider product range. In addition, growing demand for doorstep delivery, integrated cold chain logistics, and real-time inventory tracking further support this channel. In addition, partnerships between manufacturers and digital distributors, along with rising awareness of preventive animal healthcare, are accelerating the growth of e-commerce in vaccine distribution.

Regional Insights

North America dominated the market with the largest revenue share of 36.0% in 2025. This large share can be attributed to the high prevalence of livestock and zoonotic diseases leading to large-scale animal deaths. In addition, the market is anticipated to grow more quickly due to the high number of well-established pharmaceutical companies constantly working to expand their global reach and commercialize their vaccines. These companies utilize their innovative approaches to bring new products into the market. For instance, in February 2026, BioVaxys Technology Corp. and Adiverna LLC partnered to develop AI-designed mRNA vaccines for companion animals, targeting rabies, leptospirosis, and FIV using advanced DPX immune platform technology. Such innovations enable improved efficacy, longer immunity, and scalable production, accelerating next-generation vaccine adoption globally. Furthermore, the growing number of pets in the U.S. and the rising occurrence of canine diseases, which is driving up vaccine adoption, are some of the key factors contributing to the market expansion.

U.S. Animal Vaccines Market Trends

The animal vaccines market in the U.S. accounted for the highest market share in North America, owing to government-supported vaccine stockpiling, disease surveillance expansion, rising zoonotic threats, accelerated vaccine R&D, and large-scale manufacturing investments. In the U.S., initiatives such as those of December 2025, USDA APHIS vaccine bank strengthen outbreak preparedness and ensure rapid response capacity. In addition, programs such as nationwide milk testing for H5N1 enhance disease surveillance and drive demand for advanced vaccines. Furthermore, increasing approvals for bovine vaccine trials further accelerates innovation. Meanwhile, in March 2025, Merck & Co., Inc. invested significantly in vaccine manufacturing capacity that intensifies competition, boosts supply capabilities, and supports technological advancements.

Canada animal vaccines market is expected to grow at a significant CAGR during the forecast period, propelled by livestock disease preparedness programs, international regulatory collaboration, and public-private partnerships. For instance, in June 2025, the Canadian Food Inspection Agency established a foot-and-mouth disease vaccine bank, enhancing livestock protection, encouraging supplier participation from players such as Boehringer Ingelheim and Biogénesis Bagó. In addition, regulatory cooperation streamlines approvals, intensifies competition, and accelerates innovation. For instance, in December 2025, CFIA and the Veterinary Medicines Directorate regulatory bodies signed an MOU to enhance regulatory oversight for biologics and animal vaccines. Such factors boost the market growth.

Europe Animal Vaccines Market Trends

The animal vaccines market in Europe was identified as a lucrative region, driven by increased cat and dog use as pets and pet care expenditure. For instance, according to the FEDIAF Report of July 2025, Europe’s pet population reached 299 million, rising from 296 million the previous year, an increase of nearly 3 million. Amongst which cats accounted for 108 million, while dogs accounted for a total of 90 million. Regular vaccination is essential because pets, particularly dogs and cats, are vulnerable to a number of infectious diseases, including rabies, distemper, parvovirus, and feline leukemia. In addition, some of the programs are also increasing awareness among the people. For instance, in April 2025, on World Animal Vaccination Day, European veterinary groups urged the EU to adopt proactive vaccination strategies, citing rising transboundary diseases, climate impacts, and the need to shift from reactive control to preventive healthcare.

The UK animal vaccines market held the largest share in 2025, due to strengthened vaccine supply frameworks, increasing R&D in alternative testing models, rising avian influenza outbreaks, and government-supported innovation initiatives. The market is characterized by a veterinary medicines directorate framework that improves vaccine availability and resilience, encouraging industry participation as of September 2025. In addition, collaborative research is strengthening innovations in the country. For instance, in January 2026, institutions such as The Pirbright Institute accelerate innovation in disease modeling. Moreover, the country is witnessing avian influenza vaccine trials in March 2026, supported by the Department for Environment, Food & Rural Affairs, intensifying competition and driving the development of advanced vaccines.

The animal vaccines market in Germany is growing significantly over the forecast period in Europe. The country’s growth is influenced by growing vaccine R&D collaboration, pandemic preparedness initiatives, advanced manufacturing capabilities, and strong public-private partnerships. Participation in the European Vaccines Hub for Pandemic Readiness strengthens innovation through coordinated research, clinical development, and scalable manufacturing. Institutions like the German Center for Infection Research are enhancing Germany’s leadership in vaccine production and technology platforms. This integrated ecosystem intensifies competition, accelerates pipeline development, and positions Germany as a key hub for advanced veterinary and zoonotic vaccine innovation.

Asia Pacific Animal Vaccines Market Trends

The animal vaccines market in the Asia Pacific is expected to grow at the fastest CAGR over the forecast period. The anticipated rise in the livestock population and government initiatives, especially in developing economies, are some of the major factors expected to boost market growth in the region. Moreover, the large cattle population in the country calls for vaccine demand. The market is driven by high R&D expenditures by many major players, combined with rising attempts to commercialize veterinary vaccines and inoculations at tolerably low prices.

China animal vaccines market held the largest revenue share and is witnessing new growth opportunities due to domestic vaccine innovation, import substitution, cost-effective alternatives, technological advancements, and new regulatory approvals. The country is advancing due to increasing local production and innovation. For instance, in April 2026, Tianjin Ringpu Bio-Technology Co launched China’s first domestically developed feline trivalent vaccine, breaking the long-standing monopoly of Zoetis Inc. and improving affordability and accessibility. In addition, in April 2025, AIM Vaccine Co., Ltd. advanced a serum-free rabies vaccine, highlighting technological progress and intensifying competitive dynamics. Such factors are driving market growth.

The animal vaccines market in India is witnessing notable growth due to government support, expanding manufacturing infrastructure, innovation hubs, and rising focus on One Health initiatives. The country is witnessing coordinated efforts that are strengthening market competitiveness. For instance, in September 2025, the formation of the Veterinary Vaccine India Manufacturers Association unified key players to enhance policy advocacy, innovation, and global positioning. In addition, the expansion of vaccine manufacturing units is driving the need for innovative animal vaccines. For instance, in February 2026, new animal vaccine manufacturing projects and AI-driven innovation hubs announced at BioAsia in Hyderabad are expanding production capacity and accelerating technological advancements, fostering sustained market growth. Such factors are responsible for market growth.

Latin America Animal Vaccines Market Trends

The animal vaccines market in Latin America is driven by increasing reforms in the healthcare industry in this region. The rising incidence of chronic livestock diseases is a factor driving market growth. Furthermore, the rise in supportive government funding in countries such as Brazil is another contributing factor. The presence of untapped opportunities, economic development, and rising awareness levels are some of the factors that can account for the rapid growth of this region.

Brazil animal vaccines market is gaining momentum due to strong surveillance programs, vaccine bank development, export-oriented livestock growth, and technology transfer initiatives. The country’s growth is also attributed to advancements in animal health that is transforming market dynamics. For instance, in June 2025, recognition by the World Organization for Animal Health as FMD-free without vaccination strengthened export potential and reduced routine vaccine dependence. In addition, growing collaborations between key players and government institutions are also advancing market growth. For instance, in January 2026, collaboration between Paraná Technological Institute (Tecpar) and Biogénesis Bagó to establish a vaccine bank enhances outbreak preparedness, intensifies competition, and drives innovation in vaccine supply systems.

Middle East & Africa Animal Vaccines Market Trends

The animal vaccines market in MEA is advancing, due to high incidence of diseases such as animal influenza and viral diseases, such as foot-and-mouth disease, coupled with rising awareness. These factors increased the need for effective management of the aforementioned chronic diseases in regions such as South Africa. The rising urgency can be attributed to inadequate treatment alternatives present in this region. The growing consumer preference for a healthy lifestyle is also fueling the market. In addition, to boost regional competitiveness and accelerate growth of the veterinary vaccine market across the Middle East and Africa, AAAID, in June 2025, supported the inauguration of Middle East for Vaccines (MEVAC), an expanded veterinary vaccine facility in Egypt, featuring 12 billion doses of capacity and an advanced R&D center, strengthening regional production and innovation capabilities.

South Africa animal vaccines market is growing due to government-led vaccination campaigns, emergency vaccine approvals, rising disease outbreaks, import facilitation mechanisms, and focus on food security. In South Africa, recent disease outbreaks are accelerating vaccine demand. For instance, in March 2026, nationwide FMD vaccination campaigns led by the government expanded coverage and boosted vaccine consumption. Due to this, in February 2026, the South African Health Products Regulatory Authority fast-tracked import approval for FMD vaccines, improving accessibility. These initiatives intensify supplier participation, strengthen distribution networks, and enhance competitive dynamics, driving market growth. Furthermore, the rising number of partnerships for the manufacturing of innovative vaccines is boosting market growth. For instance, in February 2025, EVA Pharma, DNA Script, and Quantoom Biosciences partnered to develop an end-to-end mRNA vaccine platform targeting human and animal health across Africa. Such factors propel market growth.

Saudi Arabia animal vaccines market is fueled by government-led initiatives, localization of vaccine production, technology transfer, and rising focus on food security. Some of the strategic initiatives are transforming the market. For instance, in December 2025, government programs promoted domestic vaccine production and launched a Veterinary Biotech Park to attract global players and enhance R&D. In addition, growing partnerships between the established players and the government of Saudi Arabia are boosting market growth. For instance, in February 2026, collaboration between Ceva Santé Animale and the government supports technology transfer and local manufacturing, intensifying competition and improving supply resilience.

Key Animal Vaccines Company Insights

The market is moderately competitive, marked by various small and large animal vaccine manufacturers. The key parameters affecting competition include the rapid adoption of veterinary preventive injections and government-aided bulk purchase of veterinary vaccines. In addition, to retain shares and diversify the product portfolio, major players frequently opt for various strategies such as mergers and acquisitions, partnerships, and new product launches.

Recent Developments

• In February 2026, Saudi Arabia signed an MoU with Ceva Santé Animale to localize veterinary vaccine production, focusing on mRNA, MERS-CoV, and rabies vaccines, enhancing domestic capabilities and industry development. Such an initiative strengthened local manufacturing, reduced import dependency, boosted innovation, and intensified competition in the regional market.

• In February 2026, Boehringer Ingelheim voluntarily recalled a batch of IMRAB rabies vaccines in the U.S. after quality issues, notifying veterinarians and recommending revaccination to maintain disease protection. Such an initiative highlights quality control importance, increasing regulatory scrutiny, trust concerns, and driving demand for reliable, high-quality vaccine manufacturers.

• In January 2026, HIPRA and Elanco Animal Health partnered to introduce avian metapneumovirus vaccines in the U.S., addressing respiratory disease challenges in poultry production systems. This expands product availability, enhances disease prevention, and strengthens competitive positioning through strategic collaborations and advanced vaccine solutions.

Animal Vaccines Market Report Scope

Global Animal Vaccines Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global animal vaccines market report based on product, animal, route of administration, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Attenuated Live Vaccines

  • Inactivated Vaccines

  • Subunit Vaccines

  • DNA & RNA Vaccines

  • Recombinant Vaccines

  • Autologous Vaccines

  • Other Vaccines

• Animal Outlook (Revenue, USD Million, 2021 - 2033)

  • Livestock

    • Poultry

    • Aqua

    • Ruminants

    • Swine

  • Companion

    • Canine

    • Feline

    • Equine

    • Others

• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)

  • Injectable

    • Subcutaneous

    • Intramuscular

    • Intradermal

    • Intraperitoneal

  • Oral

  • Other Routes

• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Retail

  • E-Commerce

  • Hospital/ Clinic Pharmacy

  • Veterinary Supply Distributors

  • Other Channels

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • UAE

    • Saudi Arabia

    • Kuwait

    • Qatar

    • Oman